Cellectis S.A.

18.65-0.7500-3.87%Vol 291.64K1Y Perf 48.02%
Apr 19th, 2021 16:00 DELAYED
BID18.51 ASK20.58
Open19.42 Previous Close19.40
Pre-Market- After-Market18.65
 - -  - -%
Target Price
33.20 
Analyst Rating
Strong Buy 1.00
Potential %
78.02 
Finscreener Ranking
★★★★+     55.99
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     48.01
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     53.99
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap797.85M 
Earnings Rating
Sell
Price Range Ratio 52W %
30.30 
Earnings Date
5th May 2021

Today's Price Range

18.6419.87

52W Range

11.6734.71

5 Year PE Ratio Range

-26.60-10.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.01%
1 Month
-12.97%
3 Months
-43.64%
6 Months
3.15%
1 Year
48.02%
3 Years
-37.23%
5 Years
-36.76%
10 Years
-

TickerPriceChg.Chg.%
CLLS18.65-0.7500-3.87
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Financial StrengthValueIndustryS&P 500US Markets
5.50
6.10
0.28
0.40
-26.10
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
25.70
-129.00
-115.50
-429.20
-86.60
RevenueValueIndustryS&P 500US Markets
23.82M
0.55
41.25
-7.91
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.01-0.955.94
Q03 2020-0.69-0.71-2.90
Q02 2020-0.73-0.76-4.11
Q01 2020-0.590.47179.66
Q04 2019-0.84-0.88-4.76
Q03 2019-0.89-0.3857.30
Q02 2019-0.61-0.79-29.51
Q01 2019-0.63-0.3642.86
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.82-2.50Negative
6/2021 QR-0.64-20.75Negative
12/2021 FY-2.98-49.75Negative
12/2022 FY-2.5131.04Positive
Next Report Date5th May 2021
Estimated EPS Next Report-0.82
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume291.64K
Shares Outstanding42.78M
Trades Count3.23K
Dollar Volume7.54M
Avg. Volume428.92K
Avg. Weekly Volume168.38K
Avg. Monthly Volume367.20K
Avg. Quarterly Volume426.31K

Cellectis S.A. (NASDAQ: CLLS) stock closed at 18.65 per share at the end of the most recent trading day (a -3.87% change compared to the prior day closing price) with a volume of 296.34K shares and market capitalization of 797.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 264 people. Cellectis S.A. CEO is Andre Choulika.

The one-year performance of Cellectis S.A. stock is 48.02%, while year-to-date (YTD) performance is -31.08%. CLLS stock has a five-year performance of -36.76%. Its 52-week range is between 11.67 and 34.71, which gives CLLS stock a 52-week price range ratio of 30.30%

Cellectis S.A. currently has a PE ratio of -10.10, a price-to-book (PB) ratio of 3.00, a price-to-sale (PS) ratio of 35.05, a price to cashflow ratio of 265.50, a PEG ratio of 2.32, a ROA of -16.57%, a ROC of -17.29% and a ROE of -26.21%. The company’s profit margin is -86.60%, its EBITDA margin is -115.50%, and its revenue ttm is $23.82 Million , which makes it $0.55 revenue per share.

Of the last four earnings reports from Cellectis S.A., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.82 for the next earnings report. Cellectis S.A.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Cellectis S.A. is Strong Buy (1), with a target price of $33.2, which is +78.02% compared to the current price. The earnings rating for Cellectis S.A. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cellectis S.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cellectis S.A. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.31, ATR14 : 1.83, CCI20 : -69.97, Chaikin Money Flow : 0.20, MACD : -1.87, Money Flow Index : 71.49, ROC : -7.72, RSI : 41.37, STOCH (14,3) : 9.65, STOCH RSI : 0.11, UO : 36.09, Williams %R : -90.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cellectis S.A. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (100.00 %)
7 (87.50 %)
6 (85.71 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (12.50 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.25
Strong Buy
1.29

Cellectis S.A.

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. The company reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

CEO: Andre Choulika

Telephone: +33 181691600

Address: 8 rue de la Croix Jarry, Paris 75013, , FR

Number of employees: 264

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

73%27%

Bearish Bullish

55%45%

Bearish Bullish

58%42%

News

Stocktwits